146 related articles for article (PubMed ID: 18714319)
21. [Application of warfarin pharmacogenetics].
Vasků A
Vnitr Lek; 2009 Jun; 55(6):541. PubMed ID: 19662883
[No Abstract] [Full Text] [Related]
22. [Pharmacogenetics in practice].
Spigset O
Tidsskr Nor Laegeforen; 2008 Aug; 128(15):1679. PubMed ID: 18720559
[No Abstract] [Full Text] [Related]
23. Warfarin: an old drug but still interesting.
Johnson JA
Pharmacotherapy; 2008 Sep; 28(9):1081-3. PubMed ID: 18752378
[No Abstract] [Full Text] [Related]
24. [Human genome sequencing--next generation technology or will the routine sequencing of human genome be possible?].
Pospísilová S; Tichý B; Mayer J
Cas Lek Cesk; 2009; 148(7):296-302. PubMed ID: 19642294
[TBL] [Abstract][Full Text] [Related]
25. Finding a liability-free space in which personalized medicine can bloom.
Evans BJ
Clin Pharmacol Ther; 2007 Oct; 82(4):461-5. PubMed ID: 17713468
[TBL] [Abstract][Full Text] [Related]
26. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine.
Garrison LP; Austin MJ
Health Aff (Millwood); 2006; 25(5):1281-90. PubMed ID: 16966724
[TBL] [Abstract][Full Text] [Related]
27. Warfarin revisited.
Deykin D
N Engl J Med; 1970 Jun; 282(26):1486. PubMed ID: 5419298
[No Abstract] [Full Text] [Related]
28. Translation towards personalized medicine in Multiple Sclerosis.
Miller A; Avidan N; Tzunz-Henig N; Glass-Marmor L; Lejbkowicz I; Pinter RY; Paperna T
J Neurol Sci; 2008 Nov; 274(1-2):68-75. PubMed ID: 18789804
[TBL] [Abstract][Full Text] [Related]
29. Personalized medicine: boon or budget-buster?
Dean CE
Ann Pharmacother; 2009 May; 43(5):958-62. PubMed ID: 19417115
[TBL] [Abstract][Full Text] [Related]
30. [Personalized medicine--genomic phase].
Brdicka R
Cas Lek Cesk; 2009; 148(10):477-80. PubMed ID: 20662409
[TBL] [Abstract][Full Text] [Related]
31. The art and science of personalized medicine.
Piquette-Miller M; Grant DM
Clin Pharmacol Ther; 2007 Mar; 81(3):311-5. PubMed ID: 17339856
[No Abstract] [Full Text] [Related]
32. Patient-tailored medicine, Part one: the impact of race and genetics on medicine.
Braff JP; Chatterjee B; Hochman M; Kelton T; Kennington J; Kolavala C; Layman K; Parver C; Selby MC; Washlick JR; Wolf R
J Health Life Sci Law; 2008 Oct; 2(1):1-3, 5-36. PubMed ID: 19004296
[TBL] [Abstract][Full Text] [Related]
33. Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.
Dhanda DS; Guzauskas GF; Carlson JJ; Basu A; Veenstra DL
Clin Pharmacol Ther; 2017 Nov; 102(5):805-814. PubMed ID: 28187492
[TBL] [Abstract][Full Text] [Related]
34. The Affymetrix DMET platform and pharmacogenetics in drug development.
Deeken J
Curr Opin Mol Ther; 2009 Jun; 11(3):260-8. PubMed ID: 19479659
[TBL] [Abstract][Full Text] [Related]
35. [A 60-year-old man with heart failure, dry cough and elevated INR values].
Kamal Z; Nordstad MG; Molden E
Tidsskr Nor Laegeforen; 2008 Aug; 128(15):1677-9. PubMed ID: 18720558
[No Abstract] [Full Text] [Related]
36. Integrating personalized genomic medicine into routine clinical care: addressing the social and policy issues of pharmacogenomic testing.
Dressler LG
N C Med J; 2013; 74(6):509-13. PubMed ID: 24316779
[TBL] [Abstract][Full Text] [Related]
37. Genes versus cancer.
Lewis R
Nature; 2007 Apr; 446(7137):826-7. PubMed ID: 17460827
[No Abstract] [Full Text] [Related]
38. Pharmacogenetics in hemostasis: friend or foe?
Rumilla K; Chen D; Baudhuin LM
Semin Thromb Hemost; 2009 Feb; 35(1):42-9. PubMed ID: 19308892
[TBL] [Abstract][Full Text] [Related]
39. The genomics and Personalized Medicine Act of 2006.
Obama B
Clin Adv Hematol Oncol; 2007 Jan; 5(1):39-40. PubMed ID: 17339825
[No Abstract] [Full Text] [Related]
40. Pharmacogenomics and the challenge of health disparities.
Lee SS
Public Health Genomics; 2009; 12(3):170-9. PubMed ID: 19204420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
